Literature DB >> 9089751

Neuromuscular transmission and its pharmacological blockade. Part 3: Continuous infusion of relaxants and reversal and monitoring of relaxation.

L H Booij1.   

Abstract

Continuous infusion is an attractive method of administration when muscle relaxation is needed for a longer period. The pharmacokinetic behaviour of a drug is an important determining factor for the suitability of relaxants for continuous infusion. At present mainly intermediately long acting relaxants are used for this purpose. At the end of surgery residual curarization may exist and thus anaesthesiologists prefer to be able to reverse the relaxants. The anticholinesterases neostigmine, pyridostigmine, and edrophonium are used clinically for this reason. Their effect is prolonged in patients with renal failure, and also affected during acid-base disturbances. Some other drugs have been used experimentally for the reversal of neuromuscular blockade, but are inadequate. Special problems can arise when reversal of a mivacurium-induced or antibiotic-induced blockade is wanted, or mivacurium was administered. Monitoring neuromuscular transmission is an important feature to determine the effect of relaxant administration or to detect residual curarization. It is based on stimulation of peripheral nerves with either single twitch, train of four, tetanic or double burst stimulation. The evoked response can be quantitated with mechanomyography, electromyography, or accelerography. The response of the various muscles to nerve stimulation varies due to the different characteristics of the muscles. Clinically, the use of the adductor pollicis muscle is advised.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9089751     DOI: 10.1023/a:1008645511543

Source DB:  PubMed          Journal:  Pharm World Sci        ISSN: 0928-1231


  136 in total

1.  Comparison of anticholinesterases and their effects on acetylcholine-activated ion channels.

Authors:  R E Wachtel
Journal:  Anesthesiology       Date:  1990-03       Impact factor: 7.892

2.  A comparative study of galanthamine hydrobromide and atropine-neostigmine in conscious volunteers.

Authors:  D A Cozanitis; E Toivakka
Journal:  Anaesthesist       Date:  1971-11       Impact factor: 1.041

Review 3.  Antibiotics and neuromuscular function.

Authors:  M D Sokoll; S D Gergis
Journal:  Anesthesiology       Date:  1981-08       Impact factor: 7.892

4.  Renal failure and postoperative respiratory failure: recurarization?

Authors:  R D Miller; D J Cullen
Journal:  Br J Anaesth       Date:  1976-03       Impact factor: 9.166

5.  Determinants of the reversal time of competitive neuromuscular block by anticholinesterases.

Authors:  G H Beemer; A R Bjorksten; P J Dawson; R J Dawson; P J Heenan; B A Robertson
Journal:  Br J Anaesth       Date:  1991-04       Impact factor: 9.166

6.  Use of mivacurium during laparoscopic surgery: effect of reversal drugs on postoperative recovery.

Authors:  Y Ding; B Fredman; P F White
Journal:  Anesth Analg       Date:  1994-03       Impact factor: 5.108

7.  Impaired neostigmine antagonism of pancuronium during enflurane anaesthesia in man.

Authors:  S Delisle; D R Bevan
Journal:  Br J Anaesth       Date:  1982-04       Impact factor: 9.166

8.  Analysis of anticholinesterase-induced neuromuscular transmission failure.

Authors:  R A Maselli; C Leung
Journal:  Muscle Nerve       Date:  1993-05       Impact factor: 3.217

9.  Pharmacokinetics of galanthamine in humans and corresponding cholinesterase inhibition.

Authors:  U Bickel; T Thomsen; W Weber; J P Fischer; R Bachus; M Nitz; H Kewitz
Journal:  Clin Pharmacol Ther       Date:  1991-10       Impact factor: 6.875

10.  A prospective study of risk factors and cardiopulmonary complications associated with anaesthesia and surgery: risk indicators of cardiopulmonary morbidity.

Authors:  T Pedersen; K Eliasen; E Henriksen
Journal:  Acta Anaesthesiol Scand       Date:  1990-02       Impact factor: 2.105

View more
  1 in total

Review 1.  Rapacuronium bromide: a review of its use in anaesthetic practice.

Authors:  S V Onrust; R H Foster
Journal:  Drugs       Date:  1999-11       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.